Abstract: This composite comprises: a material having electrical conductivity; and a transition metal oxide which is supported by said material. The transition metal oxide has an amorphous structure.

Abstract: The learning system includes a data generation unit configured to generate learning data based on rehabilitation data and a learning unit configured to perform machine learning using the learning data. A sensor is provided to detect a plurality of motion amounts in a walking motion of a trainee, and it is evaluated that, when one of the motion amounts matches one of abnormal walking criteria, that the walking motion is an abnormal walking pattern that meets the matched abnormal walking criterion. The data generation unit generates each of the pieces of rehabilitation data before and after a change in the results of evaluation of the abnormal walking pattern as learning data. The learning unit sequentially inputs each of the pieces of rehabilitation data as one data set, thereby performing machine learning.

Abstract: The learning apparatus includes a data generation unit configured to generate learning data based on rehabilitation data and a learning unit configured to perform machine learning using the learning data. A sensor is provided to detect a plurality of motion amounts in a walking motion of a trainee, and it is evaluated that, when one of the motion amounts matches one of abnormal walking criteria, that the walking motion is an abnormal walking pattern that meets the matched abnormal walking criterion. The data generation unit generates each of the pieces of rehabilitation data before and after a change in the results of evaluation of the abnormal walking pattern as learning data. The learning unit sequentially inputs each of the pieces of rehabilitation data as one data set, thereby performing machine learning.

Abstract: The server is a learning apparatus including a data acquisition unit and a learning unit. The data acquisition unit acquires profile data and a selected assistance level as learning data. The profile data indicates a profile related to a trainee before executing rehabilitation regarding rehabilitation executed using a walking training apparatus as a rehabilitation support system. The selected assistance level is an assistance level selected at the time of executing the rehabilitation. The learning unit learns to determine a recommended assistance level recommended to be selected when the trainee uses the rehabilitation support system based on the learning data. Further, the learning unit generates a trained model that receives the profile data and outputs the recommended assistance level based on the learning.

Abstract: A motion state monitoring system, a training support system, a motion state monitoring method, and a program capable of suitably managing measurement results according to an attaching direction of a sensor are provided. A motion state monitoring system according to the present disclosure monitors a motion state of a target part of a subject's body. The motion state monitoring system includes an acquisition unit, an attaching direction detection unit, and a control processing unit. The acquisition unit acquires sensing information of a sensor attached to the target part. The attaching direction detection unit detects an attaching direction of the sensor. The control processing unit outputs information related to the sensing information in association with the attaching direction.

Abstract: A control system includes a communication control device including a memory, and a processor coupled to the memory and configured to execute a determination process that includes, when an operation request is received via a specific destination server, determining whether the operation request is a management operation or an application operation based on header information included in the operation request, execute a transfer process that includes, if the operation request is the application operation, transferring the operation request related to the application operation to a server running the application, and execute a blocking process that includes, if the operation request is the management operation, blocking the operation request related to the management operation.

Abstract: It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and/or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.

Abstract: An object of the present invention is to provide dermatological agents such as whitening agents and hair growth accelerators that contain a compound having high water solubility and a specific structure capable of releasing 2,3-dimethoxy-5-methyl-1,4-dihydroxybenzene (reduced form). A dermatological agent according to the present invention contains a 2,3-dimethoxy-5-methyl-1,4-dihydroxybenzenecarboxylic acid ester derivative represented by the following general Formula (I) or a salt thereof: wherein in the Formula (I), R1, R2 and R3 are specific groups.

Abstract: It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and/or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.

Abstract: A multiple-processor information processing system is capable of reducing adverse influence of overload of a given communication process on other communication processes. In this multiple-processor information processing system, a virtual IP address definition section defines virtual IP addresses on a process module-by-processor module basis. A storage device stores the virtual IP addresses defined by the virtual IP address definition section and information indicative of ones of the processor modules corresponding to the virtual IP addresses, respectively, in a state correlated with each other. A notification section notifies a router of a virtual IP address of each processor module and a real IP address of the each process module as routing information, for each processor module having the virtual IP address stored in the storage device.

Abstract: RCAS1 in a specimen is measured by a immunologically method consisting of a step of reacting a specimen with a first anti-RCAS1 antibody capable of specifically binding to RCAS1, a step of labeling the first reaction product produced by the aforementioned step, and a step of measuring a labeled amount of the labeled first reaction product. As RCAS1, recombinant RCAS1 is used. In addition, as a first anti-RCAS1, a monoclonal antibody derived from the SiSo cell line is used.

Abstract: A front-end processor and a routing management method capable of appropriately controlling the loads on respective routing paths. An Allocating section allocates a router on a first network to a routing section, and a routing information transmitting section transmits routing information to the router allocated to the routing section. The router, which is thus supplied with the routing information, accesses a server computer via the routing section, whereby the processing load of the routing section can be appropriately controlled.

Abstract: RCAS1 in a specimen is measured by a immunoglogically method consisting of a step of reacting a specimen with a first anti-RCAS1 antibody capable of specifically binding to RCAS1, a step of labeling the first reaction product produced by the aforementioned step, and a step of measuring a labeled amount of the labeled first reaction product. As RCAS1, recombinant RCAS1 is used. In addition, as a first anti-RCAS1, a monoclonal antibody derived from the SiSo cell line is used.

Abstract: There is provided a multiple-processor information processing system which is capable of reducing adverse influence of overload of a given communication process on other communication processes than the given communication process. In this multiple-processor information processing system, a virtual IP address definition section defines virtual IP addresses on a process module-by-processor module basis. A storage device stores the virtual IP addresses defined by the virtual IP address definition section and information indicative of ones of the processor modules corresponding to the virtual IP addresses, respectively, in a state correlated with each other. A notification section notifies a router of a virtual IP address of each processor module and a real IP address of the each process module as routing information, for the each processor module having the virtual IP address stored in the storage device.